- Home
- CGO vs PLRX Comparison
CGO vs PLRX Comparison
Compare CGO & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CGO | PLRX |
|---|---|---|
| Founded | 2004 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 112.9M | 79.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | CGO | PLRX |
|---|---|---|
| Price | $11.54 | $1.31 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 33.5K | ★ 597.2K |
| Earning Date | 01-01-0001 | 06-08-2026 |
| Dividend Yield | ★ 9.25% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.71 | $1.09 |
| 52 Week High | $12.79 | $1.95 |
Technical Indicators
Market Signals| Indicator | CGO | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 35.17 | 53.60 |
| Support Level | $11.37 | $1.12 |
| Resistance Level | $11.85 | $1.36 |
| Average True Range (ATR) | 0.19 | 0.06 |
| MACD | -0.10 | 0.01 |
| Stochastic Oscillator | 17.11 | 41.46 |
Price Performance
Historical ComparisonAbout CGO Calamos Global Total Return Fund
Calamos Global Total Return Fund is a closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The fund invests in equities, convertible securities, and high-yield corporate bonds.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.